{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:05Z","timestamp":1792794485443,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK MRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre for Global Infectious Disease Analysis","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}]},{"name":"Global Health EDCTP3 Joint Undertaking"},{"DOI":"10.13039\/100018336","name":"Health Protection Research Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Modelling and Health Economics"},{"name":"UKHSA","id":[{"id":"https:\/\/ror.org\/018h10037","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009660","name":"London School of Hygiene & Tropical Medicine","doi-asserted-by":"publisher","award":["NIHR200908"],"award-info":[{"award-number":["NIHR200908"]}],"id":[{"id":"10.13039\/100009660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218669\/Z\/19\/Z"],"award-info":[{"award-number":["218669\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Creative Commons Attribution","id":[{"id":"https:\/\/ror.org\/02ed4cj64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Observational evidence suggests the 4CMenB meningococcal vaccine may partially protect against gonorrhea, with 1 dose being two-thirds as protective as 2 doses. We examined the cost-effectiveness of vaccinating men who have sex with men (MSM) in England, with 1- or 2-dose primary vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Integrated transmission-dynamic health-economic modeling explored the effects of targeting strategy, first- and second-dose uptake levels, and duration of vaccine protection, using observational estimates of vaccine protection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Vaccination with 1 or 2 primary doses is always cost-saving, irrespective of uptake, although vaccine sentiment is an important determinant of impact and cost-effectiveness. The most impactful and cost-effective targeting is offering \u201cvaccination according to risk\u201d (VaR), to all patients with gonorrhea plus those reporting high numbers of sexual partners. If VaR is not feasible to implement then the more restrictive strategy of \u201cvaccination on diagnosis\u201d (VoD) with gonorrhea is cost-effective, but much less impactful. Under conservative assumptions, VaR (2-dose) saves \u00a37.62M (95% credible interval [CrI], 1.15\u201317.52) and gains 81.41 (95% CrI, 28.67\u2013164.23) quality-adjusted life-years (QALYs) over 10 years; VoD (2-dose) saves \u00a33.40M (95% CrI, .48\u20137.71) and gains 41.26 (95% CrI, 17.52\u201378.25) QALYs versus no vaccination. Optimistic versus pessimistic vaccine-sentiment assumptions increase net benefits by approximately 30% (VoD) or approximately 60% (VaR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At UK costs, targeted 4CMenB vaccination of MSM gains QALYs and is cost-saving at any uptake level. Promoting uptake maximizes benefits and is an important role for behavioral science.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae123","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T17:44:20Z","timestamp":1709833460000},"page":"71-83","source":"Crossref","is-referenced-by-count":19,"title":["Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection"],"prefix":"10.1093","volume":"231","author":[{"given":"Dariya","family":"Nikitin","sequence":"first","affiliation":[{"name":"Medical Research Council Centre for Global Infectious Disease Analysis and National Institute for Health and Care Research Health Protection Research Unit in Modelling and Health Economics, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilith K","family":"Whittles","sequence":"additional","affiliation":[{"name":"Medical Research Council Centre for Global Infectious Disease Analysis and National Institute for Health and Care Research Health Protection Research Unit in Modelling and Health Economics, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W","family":"Imai-Eaton","sequence":"additional","affiliation":[{"name":"Medical Research Council Centre for Global Infectious Disease Analysis and National Institute for Health and Care Research Health Protection Research Unit in Modelling and Health Economics, Imperial College London , London ,","place":["United Kingdom"]},{"name":"Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health , Boston, Massachusetts, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-3512","authenticated-orcid":false,"given":"Peter J","family":"White","sequence":"additional","affiliation":[{"name":"Medical Research Council Centre for Global Infectious Disease Analysis and National Institute for Health and Care Research Health Protection Research Unit in Modelling and Health Economics, Imperial College London , London ,","place":["United Kingdom"]},{"name":"Modelling and Economics Unit, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2025020417124414600_jiae123-B1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025020417124414600_jiae123-B2","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025020417124414600_jiae123-B3","doi-asserted-by":"crossref","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"key":"2025020417124414600_jiae123-B4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhoea: a global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"key":"2025020417124414600_jiae123-B5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","volume":"22","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025020417124414600_jiae123-B6","first-page":"e8","article-title":"Healthy vaccinee bias and MenB-FHbp vaccine effectiveness against gonorrhea","volume":"50","author":"Abara","year":"2023","journal-title":"Sex Transm Dis"},{"key":"2025020417124414600_jiae123-B7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2023.05.021","article-title":"4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation","volume":"87","author":"Wang","year":"2023","journal-title":"J Infect"},{"key":"2025020417124414600_jiae123-B8","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","article-title":"Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in southern California","volume":"76","author":"Bruxvoort","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025020417124414600_jiae123-B9","first-page":"247","article-title":"Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study","volume":"50","author":"Raccagni","year":"2023","journal-title":"Sex Transm Dis"},{"key":"2025020417124414600_jiae123-B10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025020417124414600_jiae123-B11","doi-asserted-by":"crossref","first-page":"e2331742","DOI":"10.1001\/jamanetworkopen.2023.31742","article-title":"Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students","volume":"6","author":"Robison","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025020417124414600_jiae123-B12","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00094-23","article-title":"Neisseria gonorrhoeae vaccines: a contemporary overview [manuscript published online ahead of print 16 January 2024]","author":"Williams","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2025020417124414600_jiae123-B13","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","article-title":"Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019","volume":"38","author":"Gottlieb","year":"2020","journal-title":"Vaccine"},{"key":"2025020417124414600_jiae123-B14","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2666-5247(22)00303-2","article-title":"The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline","volume":"4","author":"Frost","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025020417124414600_jiae123-B15","author":"Joint Committee on Vaccination and Immunisation (JCVI)"},{"key":"2025020417124414600_jiae123-B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-30992400031-8","article-title":"Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK","author":"Ladhani","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025020417124414600_jiae123-B17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","volume":"22","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025020417124414600_jiae123-B18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/OLQ.0000000000001332","article-title":"Planning for a gonococcal vaccine: a narrative review of vaccine development and public health implications","volume":"48","author":"Abara","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2025020417124414600_jiae123-B19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/antibiotics7030060","article-title":"Epidemiological trends of antibiotic resistant gonorrhoea in the United Kingdom","volume":"7","author":"Whittles","year":"2018","journal-title":"Antibiotics (Basel)"},{"key":"2025020417124414600_jiae123-B20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/OLQ.0000000000001510","article-title":"Acceptability of a gonococcal vaccine among sexually active men who have sex with men","volume":"49","author":"Abara","year":"2022","journal-title":"Sex Transm Dis"},{"key":"2025020417124414600_jiae123-B21","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.vaccine.2021.05.013","article-title":"Vaccine acceptability, uptake and completion amongst men who have sex with men: a systematic review, meta-analysis and theoretical framework","volume":"39","author":"Nadarzynski","year":"2021","journal-title":"Vaccine"},{"key":"2025020417124414600_jiae123-B22","author":"Public Health England"},{"key":"2025020417124414600_jiae123-B23","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/bjc.2015.90","article-title":"Human papillomavirus DNA in men who have sex with men: type-speci\ufb01c prevalence, risk factors and implications for vaccination strategies","volume":"112","author":"King","year":"2015","journal-title":"Br J Cancer"},{"key":"2025020417124414600_jiae123-B24","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: de\ufb01nition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"2025020417124414600_jiae123-B25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14760584.2018.1541405","article-title":"Development of a measure to assess vaccine confidence among men who have sex with men","volume":"17","author":"Frew","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2025020417124414600_jiae123-B26","doi-asserted-by":"crossref","first-page":"e1002416","DOI":"10.1371\/journal.pmed.1002416","article-title":"Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: a modelling study","volume":"14","author":"Whittles","year":"2017","journal-title":"PLoS Med"},{"key":"2025020417124414600_jiae123-B27","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025020417124414600_jiae123-B28","doi-asserted-by":"crossref","first-page":"e007776","DOI":"10.1136\/bmjopen-2015-007776","article-title":"Diagnosis and treatment of chlamydia and gonorrhoea in general practice in England 2000\u20132011: a population-based study using data from the UK Clinical Practice Research Datalink","volume":"5","author":"Wetten","year":"2015","journal-title":"BMJ Open"},{"key":"2025020417124414600_jiae123-B29","author":"National Institute for Health and Care Excellence"},{"key":"2025020417124414600_jiae123-B30","author":"Joint Committee on Vaccination and Immunisation"},{"key":"2025020417124414600_jiae123-B31","doi-asserted-by":"crossref","first-page":"e005322","DOI":"10.1136\/bmjopen-2014-005322","article-title":"Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK","volume":"4","author":"Adams","year":"2014","journal-title":"BMJ Open"},{"key":"2025020417124414600_jiae123-B32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/QAD.0000000000002469","article-title":"Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness","volume":"34","author":"Reitsema","year":"2020","journal-title":"AIDS"},{"key":"2025020417124414600_jiae123-B33","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"2025020417124414600_jiae123-B34","author":"National Health Service England"},{"key":"2025020417124414600_jiae123-B35","author":"British National Formulary"},{"key":"2025020417124414600_jiae123-B36","author":"Public Health England"},{"key":"2025020417124414600_jiae123-B37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"2025020417124414600_jiae123-B38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1086\/432004","article-title":"Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example","volume":"192","author":"White","year":"2005","journal-title":"J Infect Dis"},{"key":"2025020417124414600_jiae123-B39","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.vaccine.2013.11.007","article-title":"The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease","volume":"32","author":"Garnett","year":"2014","journal-title":"Vaccine"},{"key":"2025020417124414600_jiae123-B40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/infdis\/jiv517","article-title":"Improving control of antibiotic-resistant gonorrhea by integrating research agendas across disciplines: key questions arising from mathematical modeling","volume":"213","author":"Grad","year":"2016","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae123\/57303302\/jiae123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/71\/57303302\/jiae123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/71\/57303302\/jiae123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:18:24Z","timestamp":1738671504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/1\/71\/7646143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae123","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,4,17]]}}}